Lineage Cell Therapeutics, Inc.
DE ˙ DB ˙ US53566P1093
1,01 € ↓ -0,04 (-3,63%)
2026-06-03
DEL PRIS
SecurityDE:BT3 / Lineage Cell Therapeutics, Inc.
InstitutionRenaissance Technologies Llc
ManagerJames Simons
Latest Disclosed Ownership2,125,100 shares
Latest Disclosed Value $ 3,357,658
Renaissance Technologies Llc reports 11.63% decrease in ownership of BT3 / Lineage Cell Therapeutics, Inc.

On May 14, 2026 - Renaissance Technologies Llc filed a 13F-HR form disclosing ownership of 2,125,100 shares of Lineage Cell Therapeutics, Inc. (DE:BT3) valued at $2,677,626 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 2,404,800 shares of Lineage Cell Therapeutics, Inc.. This represents a change in shares of -11.63% during the quarter. The current value of the position is $2,146,351 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2,125,100 -279,700 -11.63 3,358 -16.41 0.0053
2026-02-12 2025-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2,404,800 499,167 26.19 4,016 24.72 0.0062
2025-11-13 2025-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,905,633 -66,702 -3.38 3,221 79.99 0.0043
2025-08-13 2025-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,972,335 -319,046 -13.92 1,790 73.02 0.0024
2025-05-14 2025-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2,291,381 8,309 0.36 1,035 -9.85 0.0016
2025-02-13 2024-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2,283,072 2,085,972 1,058.33 1,147 544.38 0.0017
2024-11-13 2024-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 197,100 -386,522 -66.23 178 -69.42 0.0003
2024-08-09 2024-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 583,622 53,022 9.99 582 0.0010
2024-05-13 2024-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 530,600 380,600 253.73 1 0.0012
2024-02-13 2023-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 150,000 90,300 151.26 0 0.0003
2023-11-14 2023-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 59,700 3,800 6.80 0 0.0001
2023-08-11 2023-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 55,900 55,900 0 0.0001
2021-05-13 2021-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 0 -23,000 -100.00 0 -100.00
2021-02-10 2020-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 23,000 -437,806 -95.01 40 -90.74 0.0000
2020-11-13 2020-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 460,806 -30,894 -6.28 432 0.93 0.0004
2020-08-13 2020-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 491,700 223,300 83.20 428 92.79 0.0004
2020-05-14 2020-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 268,400 268,400 222 0.0002
2019-05-14 2019-03-31 13F BIOTIME COM 09066L105 0 -259,300 -100.00 0 -100.00
2019-02-12 2018-12-31 13F BIOTIME COM 09066L105 259,300 259,300 237 0.0003
2018-11-13 2018-09-30 13F BIOTIME COM 09066L105 0 -145,600 -100.00 0 -100.00
2018-08-13 2018-06-30 13F/A-1 BIOTIME COM 09066L105 145,600 -630,800 -81.25 300 -85.64 0.0003
2018-08-13 2018-06-30 13F BIOTIME COM 09066L105 776,400 2,089
2018-05-14 2018-03-31 13F BIOTIME COM 09066L105 776,400 -421,400 -35.18 2,089 -18.87 0.0023
2018-02-13 2017-12-31 13F BIOTIME COM 09066L105 1,197,800 807,500 206.89 2,575 132.40 0.0028
2017-11-13 2017-09-30 13F BIOTIME COM 09066L105 390,300 264,693 210.73 1,108 179.80 0.0013
2017-08-11 2017-06-30 13F BIOTIME COM 09066L105 125,607 19,785 18.70 396 8.49 0.0005
2017-05-12 2017-03-31 13F BIOTIME COM 09066L105 105,822 105,822 365 0.0005
2016-02-11 2015-12-31 13F BIOTIME COM 09066L105 0 0 0 0.0000
2015-11-12 2015-09-30 13F BIOTIME COM 09066L105 0 -165,000 -100.00 0 -100.00
2015-08-14 2015-06-30 13F BIOTIME COM 09066L105 165,000 113,300 219.15 599 252.35 0.0014
2014-05-14 2014-03-31 13F BIOTIME COM 09066L105 51,700 51,700 170 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.